Printer Friendly
The Free Library
23,396,934 articles and books


Novel drug may take on lung cancer.

In several kinds of cancer, malignant cells display an excess of a specific type of surface receptor, which when stimulated causes unchecked growth of such cells (SN: 9/11/04, p. 164).

Scientists now report that a novel agent bottles up this so-called epidermal growth factor receptor and stalls the growth of cancer cells in a lab dish. The strong results have led the researchers to begin testing the new drug, called HKI-272, in people with lung cancer that has proved resistant to two existing anticancer drugs that target the same receptor, reports Daniel A. Haber of Massachusetts General Hospital Cancer Center in Charlestown.--N.S.
COPYRIGHT 2005 Science Service, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

 Reader Opinion

Title:

Comment:



 

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:MICROBIOLOGY; testing HKI-272 drug for lung cancer
Publication:Science News
Article Type:Brief Article
Geographic Code:1U1MA
Date:May 7, 2005
Words:106
Previous Article:Anti-inflammatories cut risk of mouth cancer.
Next Article:Insights from Insects: What Bad Bugs Can Teach Us.
Topics:



Related Articles
Gene therapy approved for lung cancer.
Transplant drug increases cancer risk.
High estrogen linked to lung cancer.
Active lung gene signals cancer spread.
ORGANON GETS FIRST EUROPEAN MARKETING APPROVAL FOR REMERON.
CANCER TREATMENT DRAWS NOTICE; SANTA CLARITA CENTER RECEIVING NUMEROUS INQUIRIES.
CYCLACEL'S CYC202 INDUCES CANCER CELLS TO COMMIT SUICIDE.
Targeted attack: scientists declare war on a protein implicated in some stubborn forms of cancer.
Agents of metastasis: four proteins conspire in breast cancer spread.

Terms of use | Copyright © 2014 Farlex, Inc. | Feedback | For webmasters